1. Medtech Insight
  2. >>Archive

Menarini CE-marks continuous glucose monitor

Menarini Diagnostics has gained European approval to sell its subcutaneous system for continuously monitoring glucose levels in diabtetics.

Menarini Diagnostics has gained European approval to sell its subcutaneous system for continuously monitoring glucose levels in diabtetics.

The walkman-sized GlucoDay device is worn in a portable pouch around the patient's waist. A microfibre, no thicker than a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

CMS Announces $50B In Grants For Rural Health Transformation

AdvaMed has praised CMS’ Rural Health Transformation Program, which will allocate $50 billion over five years to enhance rural healthcare. States can apply for grants by Nov. 5 to develop sustainable healthcare systems and improve patient outcomes.

Mental Health The Focus Of Upcoming Digital Health Advisory Committee Meeting

 
• By Brian Bossetta

The US FDA will hold a public meeting of its Digital Health Advisory Committee in November to focus on generative AI-enabled medical devices to treat mental health.

Morphic Medical Prepares RESET Rollout In UK And Germany, Eyes Global Expansion In 5 Years

 
• By Shubham Singh

The company is undergoing major leadership changes, having appointed 30-year medtech veteran Jane Wright as chief financial officer on Sept. 12. Wright’s appointment follows Gutteridge’s own transition to CEO earlier this year.